- Could Your Grocery Store Meat Be Causing Recurring UTIs?
- Are You Making This Expensive Thermostat Error This Winter?
- Recognizing the Signs of Hypothyroidism
- 10 Strategies to Overcome Insomnia
- Could Artificial Sweeteners Be Aging the Brain Faster?
- Techniques for Soothing Your Nervous System
- Does the Water in Your House Smell Funny? Here’s Why
- Can a Daily Dose of Apple Cider Vinegar Actually Aid Weight Loss?
- 6 Health Beverages That Can Actually Spike Your Blood Sugar
- Treatment Options for Social Anxiety Disorder
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without symptoms. The approval is the first for TAVR in asymptomatic patients.
In the EARLY TAVR trial, which informed the approval, patients with asymptomatic severe aortic stenosis were randomly assigned to either TAVR or watchful waiting. During a median follow-up of 3.8 years, 26.8 percent of the 455 patients in the TAVR group experienced death, stroke, or unplanned cardiovascular hospitalization compared with 45.3 percent of the 446 patients in the clinical surveillance group.
“There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend ‘watchful waiting’ until symptoms develop,” Philippe Genereux, M.D., from the Gagnon Cardiovascular Institute at Morristown Medical Center in New Jersey, said in a statement. “As we saw in the EARLY TAVR trial, patients originally designated as asymptomatic became symptomatic in sudden and unpredictable ways, underscoring the importance of early evaluation by a heart team to improve patient outcomes and benefit the health care system.”
Approval of the SAPIEN 3 platform was granted to Edwards Lifesciences.
Source: HealthDay
Copyright © 2026 HealthDay. All rights reserved.










